Review



blt2 af647  (Bioss)


Bioz Verified Symbol Bioss is a verified supplier
Bioz Manufacturer Symbol Bioss manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Bioss blt2 af647
    (A) WT CT, STZ-treated WT, STZ-treated Alox5–/–, and STZ-treated Ltb4r1–/– mice were infected s.c. with MRSA, and infection areas were measured for 9 days. (B) Bacterial CFUs in the skin at day 9 after infection. Data are mean ± SEM of 5–10 mice. *P < 0.05 vs. WT CT mice. #P < 0.05 vs. STZ-treated WT mice. (C) CT and STZ-treated mice were infected s.c. with MRSA. STZ-treated mice were treated daily with topical ointments, vehicle-control, 0.001% BLT1 antagonist (U-75302), or 0.001% <t>BLT2</t> antagonist (LY255283), and infection area was measured as in A. (D) Bacterial CFUs from mice in C at day 9 after infection. Data are mean ± SEM of 4–6 mice. *P < 0.05 vs. CT mice. #P < 0.05 vs. STZ-treated mice treated with vehicle control ointment. (E) Mice were infected s.c. with bioluminescent-expressing MRSA. Infection areas were measured every other day in CT and STZ-treated mice treated daily with vehicle control or 0.001% BLT1 antagonist (U-75302) ointments. (F) Bioluminescence imaging (BLI) to quantify bacterial burden in the skin at days 1, 3, 4, 7, and 9 after infection. (G) Representative images of bioluminescent MRSA infection in control and diabetic mice that were treated or not with BLT1 antagonist scanned by BLI. (H) Lesion size of nondiabetic NOD (ctNOD) and diabetic NOD (dbNOD) mice infected with MRSA by s.c. injection. Infected dbNOD mice were treated daily with vehicle-control or 0.001% BLT1 antagonist (U-75302) ointments as in C. Data are mean ± SEM of 5–10 mice. *P < 0.05 vs. CT mice. #P < 0.05 vs. STZ-treated mice treated with vehicle control. (I) Gram stains of CT and diabetic mice that were infected and treated with the BLT1 antagonist with MRSA for 1 and 9 after infection. Top panels show 100× and bottom panels show 1,000× magnification with an inset of a cropped zoomed view of 5 ,000× magnification. Arrows indicate bacteria.
    Blt2 Af647, supplied by Bioss, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/blt2 af647/product/Bioss
    Average 90 stars, based on 2 article reviews
    blt2 af647 - by Bioz Stars, 2026-04
    90/100 stars

    Images

    1) Product Images from "Excessive localized leukotriene B 4 levels dictate poor skin host defense in diabetic mice"

    Article Title: Excessive localized leukotriene B 4 levels dictate poor skin host defense in diabetic mice

    Journal: JCI Insight

    doi: 10.1172/jci.insight.120220

    (A) WT CT, STZ-treated WT, STZ-treated Alox5–/–, and STZ-treated Ltb4r1–/– mice were infected s.c. with MRSA, and infection areas were measured for 9 days. (B) Bacterial CFUs in the skin at day 9 after infection. Data are mean ± SEM of 5–10 mice. *P < 0.05 vs. WT CT mice. #P < 0.05 vs. STZ-treated WT mice. (C) CT and STZ-treated mice were infected s.c. with MRSA. STZ-treated mice were treated daily with topical ointments, vehicle-control, 0.001% BLT1 antagonist (U-75302), or 0.001% BLT2 antagonist (LY255283), and infection area was measured as in A. (D) Bacterial CFUs from mice in C at day 9 after infection. Data are mean ± SEM of 4–6 mice. *P < 0.05 vs. CT mice. #P < 0.05 vs. STZ-treated mice treated with vehicle control ointment. (E) Mice were infected s.c. with bioluminescent-expressing MRSA. Infection areas were measured every other day in CT and STZ-treated mice treated daily with vehicle control or 0.001% BLT1 antagonist (U-75302) ointments. (F) Bioluminescence imaging (BLI) to quantify bacterial burden in the skin at days 1, 3, 4, 7, and 9 after infection. (G) Representative images of bioluminescent MRSA infection in control and diabetic mice that were treated or not with BLT1 antagonist scanned by BLI. (H) Lesion size of nondiabetic NOD (ctNOD) and diabetic NOD (dbNOD) mice infected with MRSA by s.c. injection. Infected dbNOD mice were treated daily with vehicle-control or 0.001% BLT1 antagonist (U-75302) ointments as in C. Data are mean ± SEM of 5–10 mice. *P < 0.05 vs. CT mice. #P < 0.05 vs. STZ-treated mice treated with vehicle control. (I) Gram stains of CT and diabetic mice that were infected and treated with the BLT1 antagonist with MRSA for 1 and 9 after infection. Top panels show 100× and bottom panels show 1,000× magnification with an inset of a cropped zoomed view of 5 ,000× magnification. Arrows indicate bacteria.
    Figure Legend Snippet: (A) WT CT, STZ-treated WT, STZ-treated Alox5–/–, and STZ-treated Ltb4r1–/– mice were infected s.c. with MRSA, and infection areas were measured for 9 days. (B) Bacterial CFUs in the skin at day 9 after infection. Data are mean ± SEM of 5–10 mice. *P < 0.05 vs. WT CT mice. #P < 0.05 vs. STZ-treated WT mice. (C) CT and STZ-treated mice were infected s.c. with MRSA. STZ-treated mice were treated daily with topical ointments, vehicle-control, 0.001% BLT1 antagonist (U-75302), or 0.001% BLT2 antagonist (LY255283), and infection area was measured as in A. (D) Bacterial CFUs from mice in C at day 9 after infection. Data are mean ± SEM of 4–6 mice. *P < 0.05 vs. CT mice. #P < 0.05 vs. STZ-treated mice treated with vehicle control ointment. (E) Mice were infected s.c. with bioluminescent-expressing MRSA. Infection areas were measured every other day in CT and STZ-treated mice treated daily with vehicle control or 0.001% BLT1 antagonist (U-75302) ointments. (F) Bioluminescence imaging (BLI) to quantify bacterial burden in the skin at days 1, 3, 4, 7, and 9 after infection. (G) Representative images of bioluminescent MRSA infection in control and diabetic mice that were treated or not with BLT1 antagonist scanned by BLI. (H) Lesion size of nondiabetic NOD (ctNOD) and diabetic NOD (dbNOD) mice infected with MRSA by s.c. injection. Infected dbNOD mice were treated daily with vehicle-control or 0.001% BLT1 antagonist (U-75302) ointments as in C. Data are mean ± SEM of 5–10 mice. *P < 0.05 vs. CT mice. #P < 0.05 vs. STZ-treated mice treated with vehicle control. (I) Gram stains of CT and diabetic mice that were infected and treated with the BLT1 antagonist with MRSA for 1 and 9 after infection. Top panels show 100× and bottom panels show 1,000× magnification with an inset of a cropped zoomed view of 5 ,000× magnification. Arrows indicate bacteria.

    Techniques Used: Infection, Expressing, Imaging, Injection



    Similar Products

    blt2 af647  (Bioss)
    90
    Bioss blt2 af647
    (A) WT CT, STZ-treated WT, STZ-treated Alox5–/–, and STZ-treated Ltb4r1–/– mice were infected s.c. with MRSA, and infection areas were measured for 9 days. (B) Bacterial CFUs in the skin at day 9 after infection. Data are mean ± SEM of 5–10 mice. *P < 0.05 vs. WT CT mice. #P < 0.05 vs. STZ-treated WT mice. (C) CT and STZ-treated mice were infected s.c. with MRSA. STZ-treated mice were treated daily with topical ointments, vehicle-control, 0.001% BLT1 antagonist (U-75302), or 0.001% <t>BLT2</t> antagonist (LY255283), and infection area was measured as in A. (D) Bacterial CFUs from mice in C at day 9 after infection. Data are mean ± SEM of 4–6 mice. *P < 0.05 vs. CT mice. #P < 0.05 vs. STZ-treated mice treated with vehicle control ointment. (E) Mice were infected s.c. with bioluminescent-expressing MRSA. Infection areas were measured every other day in CT and STZ-treated mice treated daily with vehicle control or 0.001% BLT1 antagonist (U-75302) ointments. (F) Bioluminescence imaging (BLI) to quantify bacterial burden in the skin at days 1, 3, 4, 7, and 9 after infection. (G) Representative images of bioluminescent MRSA infection in control and diabetic mice that were treated or not with BLT1 antagonist scanned by BLI. (H) Lesion size of nondiabetic NOD (ctNOD) and diabetic NOD (dbNOD) mice infected with MRSA by s.c. injection. Infected dbNOD mice were treated daily with vehicle-control or 0.001% BLT1 antagonist (U-75302) ointments as in C. Data are mean ± SEM of 5–10 mice. *P < 0.05 vs. CT mice. #P < 0.05 vs. STZ-treated mice treated with vehicle control. (I) Gram stains of CT and diabetic mice that were infected and treated with the BLT1 antagonist with MRSA for 1 and 9 after infection. Top panels show 100× and bottom panels show 1,000× magnification with an inset of a cropped zoomed view of 5 ,000× magnification. Arrows indicate bacteria.
    Blt2 Af647, supplied by Bioss, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/blt2 af647/product/Bioss
    Average 90 stars, based on 1 article reviews
    blt2 af647 - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) WT CT, STZ-treated WT, STZ-treated Alox5–/–, and STZ-treated Ltb4r1–/– mice were infected s.c. with MRSA, and infection areas were measured for 9 days. (B) Bacterial CFUs in the skin at day 9 after infection. Data are mean ± SEM of 5–10 mice. *P < 0.05 vs. WT CT mice. #P < 0.05 vs. STZ-treated WT mice. (C) CT and STZ-treated mice were infected s.c. with MRSA. STZ-treated mice were treated daily with topical ointments, vehicle-control, 0.001% BLT1 antagonist (U-75302), or 0.001% BLT2 antagonist (LY255283), and infection area was measured as in A. (D) Bacterial CFUs from mice in C at day 9 after infection. Data are mean ± SEM of 4–6 mice. *P < 0.05 vs. CT mice. #P < 0.05 vs. STZ-treated mice treated with vehicle control ointment. (E) Mice were infected s.c. with bioluminescent-expressing MRSA. Infection areas were measured every other day in CT and STZ-treated mice treated daily with vehicle control or 0.001% BLT1 antagonist (U-75302) ointments. (F) Bioluminescence imaging (BLI) to quantify bacterial burden in the skin at days 1, 3, 4, 7, and 9 after infection. (G) Representative images of bioluminescent MRSA infection in control and diabetic mice that were treated or not with BLT1 antagonist scanned by BLI. (H) Lesion size of nondiabetic NOD (ctNOD) and diabetic NOD (dbNOD) mice infected with MRSA by s.c. injection. Infected dbNOD mice were treated daily with vehicle-control or 0.001% BLT1 antagonist (U-75302) ointments as in C. Data are mean ± SEM of 5–10 mice. *P < 0.05 vs. CT mice. #P < 0.05 vs. STZ-treated mice treated with vehicle control. (I) Gram stains of CT and diabetic mice that were infected and treated with the BLT1 antagonist with MRSA for 1 and 9 after infection. Top panels show 100× and bottom panels show 1,000× magnification with an inset of a cropped zoomed view of 5 ,000× magnification. Arrows indicate bacteria.

    Journal: JCI Insight

    Article Title: Excessive localized leukotriene B 4 levels dictate poor skin host defense in diabetic mice

    doi: 10.1172/jci.insight.120220

    Figure Lengend Snippet: (A) WT CT, STZ-treated WT, STZ-treated Alox5–/–, and STZ-treated Ltb4r1–/– mice were infected s.c. with MRSA, and infection areas were measured for 9 days. (B) Bacterial CFUs in the skin at day 9 after infection. Data are mean ± SEM of 5–10 mice. *P < 0.05 vs. WT CT mice. #P < 0.05 vs. STZ-treated WT mice. (C) CT and STZ-treated mice were infected s.c. with MRSA. STZ-treated mice were treated daily with topical ointments, vehicle-control, 0.001% BLT1 antagonist (U-75302), or 0.001% BLT2 antagonist (LY255283), and infection area was measured as in A. (D) Bacterial CFUs from mice in C at day 9 after infection. Data are mean ± SEM of 4–6 mice. *P < 0.05 vs. CT mice. #P < 0.05 vs. STZ-treated mice treated with vehicle control ointment. (E) Mice were infected s.c. with bioluminescent-expressing MRSA. Infection areas were measured every other day in CT and STZ-treated mice treated daily with vehicle control or 0.001% BLT1 antagonist (U-75302) ointments. (F) Bioluminescence imaging (BLI) to quantify bacterial burden in the skin at days 1, 3, 4, 7, and 9 after infection. (G) Representative images of bioluminescent MRSA infection in control and diabetic mice that were treated or not with BLT1 antagonist scanned by BLI. (H) Lesion size of nondiabetic NOD (ctNOD) and diabetic NOD (dbNOD) mice infected with MRSA by s.c. injection. Infected dbNOD mice were treated daily with vehicle-control or 0.001% BLT1 antagonist (U-75302) ointments as in C. Data are mean ± SEM of 5–10 mice. *P < 0.05 vs. CT mice. #P < 0.05 vs. STZ-treated mice treated with vehicle control. (I) Gram stains of CT and diabetic mice that were infected and treated with the BLT1 antagonist with MRSA for 1 and 9 after infection. Top panels show 100× and bottom panels show 1,000× magnification with an inset of a cropped zoomed view of 5 ,000× magnification. Arrows indicate bacteria.

    Article Snippet: The following antibodies were utilized: BLT1-PE (BD Biosciences; catalog 552836; clone 203/14F11), BLT2-AF647 (Bioss; catalog bs-2655R-A647; polyclonal), Ly6G-AF488 (BioLegend; catalog 127626; clone 1A8),Ly6G-PerCPCy5.5 (BioLegend; catalog 127616; clone 1A8), F4/80-PE (BioLegend; catalog 123110; clone BM8), F4/80-AF700 (BioLegend; catalog 123130; clone BM8), CD45-Pacific blue (BioLegend; catalog 103126; clone 30-F11), mouse CD16/32 Fc blocking antibody (BioLegend; catalog 101320; clone 93), and Zombie UV viability dye (BioLegend; catalog 423107).

    Techniques: Infection, Expressing, Imaging, Injection